{"organizations": [], "uuid": "24cd0d89216d4b8daa08d0e550815de77b4d5ed1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cytodyn-reports-primary-endpoint-a/brief-cytodyn-reports-primary-endpoint-achieved-in-pro-140-pivotal-combination-therapy-trial-in-hiv-infection-idUSFWN1QA0EJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Cytodyn Reports Primary Endpoint Achieved In PRO 140 Pivotal Combination Therapy Trial In HIV Infection", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.64, "site_type": "news", "published": "2018-02-20T19:18:00.000+02:00", "replies_count": 0, "uuid": "24cd0d89216d4b8daa08d0e550815de77b4d5ed1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cytodyn-reports-primary-endpoint-a/brief-cytodyn-reports-primary-endpoint-achieved-in-pro-140-pivotal-combination-therapy-trial-in-hiv-infection-idUSFWN1QA0EJ", "ord_in_thread": 0, "title": "BRIEF-Cytodyn Reports Primary Endpoint Achieved In PRO 140 Pivotal Combination Therapy Trial In HIV Infection", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cytodyn inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Cytodyn Inc:\n* CYTODYN REPORTS PRIMARY ENDPOINT ACHIEVED IN PRO 140 PIVOTAL COMBINATION THERAPY TRIAL IN HIV INFECTION\n* CYTODYN INC - TRIAL DATA SHOW A STATISTICALLY SIGNIFICANT REDUCTION IN HIV-1 RNA VIRAL LOAD OF GREATER THAN 0.5LOG WITH PRO 140 VERSUS PLACEBO\n* CYTODYN INC - TO DATE, PRO 140 HAS BEEN GENERALLY WELL TOLERATED WITH NO DRUG-RELATED MAJOR ADVERSE EVENTS OR TREATMENT DISCONTINUATION REPORTED Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T19:18:00.000+02:00", "crawled": "2018-02-21T21:46:56.006+02:00", "highlightTitle": ""}